Abstract
Introduction Polymyxins, the cationic lipopeptide antibiotics, are the last line of therapeutics against the multi-drug resistant (MDR) pathogenic Gram-negative bacteria. Unfortunately, the rising cases of polymyxin-resistant strains from across the globe have adversely impacted the available treatment options. While the molecular mechanisms responsible for developing polymyxin resistance (PolR) are largely understood, the prevalence of PolR strains in India is not investigated systematically.
Method For this study, a systematic search for relevant articles was performed in the applicable databases for the period January 2015 to December 2023. A meta-analysis was performed using the comprehensive meta-analysis software (V.4) to determine the overall prevalence of PolR bacterial strains in India. Publication biases were assessed using funnel plots and Egger’s regression analysis.
Result Considering a total of 43 studies selected based on the relevant inclusion and exclusion criteria, the present meta-analysis found the rate of PolR bacteria in India to be at 15.7%, which is higher than the global average. Among the Indian States, Tamil Nadu topped with the highest prevalence of PolR at 32.4%. Investigating the contribution of the mobile colistin resistance (mcr) genes, it was observed that among the PolR strains, 8.6 % were mcr positive.
Conclusion The mcr-positive strains reported from India could be an underestimation of the actual numbers due to the non-inclusion of mcr screening in many previous studies. Our study provides insight into the state of the PolR situation in India, which may be useful to develop a monitoring strategy to contain the spread of such strains and preserve the potency of the polymyxins.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the funds received from the Science and Technology Department, Govt. of Odisha Grant no. ST-BT-MISC-0005-2023-2463/ST.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The manuscript has been revised to update the inclusion/exclusion criteria used for performing the meta-analysis. Specifically, the use of broth microdilution method to determine polymyxin resistance has been used as the inclusion criterion to select studies for meta-analysis. Therefore, with the revision, the figures 1, 2,3, and 5 have been updated. Moreover, the supplementary file is also updated.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.